FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry and namely to an antagonist antibody or its binding fragment that specifically binds to human TGF-beta 1, human TGF-beta 2 and human TGF-beta 3, to a method for its production as well as to an isolated DNA sequence encoding its light and heavy chain; and compositions containing it. Also disclosed are a vector, host cell containing the above DNA sequence. The invention also relates to the use of the above antibody or a fragment thereof in the manufacture of a medicament for the treatment or prevention of a pathological disorder mediated by TGF-beta 1, 2 or 3 or which is associated with an increased level of TGF-beta 1, 2 or 3 as well as in the manufacture a medicament for the treatment or prevention of a pulmonary disorder which is mediated by TGF-beta 1, 2 or 3, or which is associated with an increased level of TGF-beta 1, 2 or 3.
EFFECT: invention makes it possible to effectively treat a patient suffering from or at risk of a pathological disorder mediated by TGF-beta 1, 2 or 3, or associated with an increased level of TGF-beta 1, 2 or 3.
28 cl, 13 tbl, 12 ex, 18 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TGF-BETA RECEPTOR ECTODOMAIN FUNCTIONS AND THEIR USE | 2018 |
|
RU2797464C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| POLYFUNCTIONAL PROTEIN MOLECULES CONTAINING DECORIN AND USE THEREOF | 2019 |
|
RU2823357C2 |
| MOLECULES OF ANTIBODIES TO CD73 AND THEIR APPLICATION WAYS | 2018 |
|
RU2791192C2 |
| TGFβR2 MOLECULE WITH TRUNCATED EXTRACELLULAR DOMAIN, FUSION PROTEIN OF TGFβR2 MOLECULE WITH TRUNCATED EXTRACELLULAR DOMAIN, AND ANTI-EGFR ANTIBODIES, AND ANTI-TUMOUR USE OF FUSED PROTEIN | 2021 |
|
RU2824199C1 |
| GENE CONSTRUCT FOR THE EXPRESSION OF RECOMBINANT PROTEINS BASED ON THE SEGMENT OF THE SARS-COV-2 S-PROTEIN, INCLUDING RBD AND SD1, FUSED WITH THE FC FRAGMENT OF IGG, A METHOD OF OBTAINING RECOMBINANT PROTEINS, ANTIGENS AND ANTIGENIC COMPOSITIONS FOR THE INDUCTION OF LONG-TERM ANTIBODY AND CELLULAR IMMUNITY AGAINST SARS-CO-2 | 2021 |
|
RU2802825C2 |
